Aspirin is a nonsteroidal anti-inflammatory drug
(NSAID).
Aspirin is a
nonsteroidal anti-inflammatory drug (NSAID). It has analgesic, antipyretic,
antirheumatic, and anti-inflammatory properties. Its action may be due to
inhibition of synthesis and release of prostaglandins. It is used to treat
pain, inflammation associated with various conditions (including rheumatoid
arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus,
osteoarthritis, and ankylosing spondylitis) and nonfatal myocardial infarction.
Pharmacological Class: NSAID
Aspirin
directly and irreversibly inhibits the activity of both types of cyclooxygenase
(COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and
thromboxanes from arachidonic acid. It may competitively inhibit prostaglandin
formation. The platelet aggregation-inhibiting effect of aspirin specifically
involves its ability to act as an acetyl donor to cyclooxygenase.
Irreversible acetylation
renders cyclooxygenase inactive, thereby preventing the formation of the
aggregating agent thromboxane A2 in platelets. Since platelets lack the ability
to synthesize new proteins, the effects persist for the life of the exposed
platelets (7-10 days). Aspirin may also inhibit production of the platelet
aggregation inhibitor, prostacyclin (prostaglandin I2), by blood vessel
endothelial cells.
Osteoarthritis: 3 grams per day in divided doses
Rheumatoid Arthritis: 3 grams per day in divided doses
Ankylosing Spondylitis: 3 grams per day in divided doses
Fever: 325 to 650 mg orally or rectally every 4 hours as needed
Rheumatic fever: 80 mg/kg/day orally in 4 equally divided doses, up to 6.5 g/day
SLE: 3 grams per day in divided doses
Aspirin is absorbed rapidly in gastrointestinal
tract. It is
rapidly hydrolyzed primarily in the liver to salicylic acid, which is
conjugated with glycine (forming salicyluric acid) and glucuronic acid and
excreted largely in the urine.
Common (affecting between 1 in 10 to 1 in 100):
Uncommon (affecting 1 in 100 to 1 in 1000):
Very rare (affecting less than 1 in 10,000):
Seventy-two randomized single-dose trials with 3253 patients given aspirin, and 3297 were given placebo. Significant benefit of aspirin over placebo was shown for aspirin 600/650 mg, 1000 mg and 1200 mg, with numbers-needed-to-treat for at least 50% pain relief of 4.4 (4.0-4.9), 4.0 (3.2-5.4) and 2.4 (1.9-3.2) respectively. Type of pain model, pain measurement, sample size, quality of study design, and study duration had no significant impact on the results. There was a clear dose-response for pain relief with aspirin, even though these were single dose studies.1
Comments (0)